XIN Stock Chart & Stats
€0.70
-€0.02(-2.88%)
At close: 4:00 PM EST
€0.70
-€0.02(-2.88%)
Day’s Range― - ―
52-Week Range€0.57 - €0.89
Previous CloseN/A
Volume0.00
Average Volume (3M)91.00
Market Cap
€1.01B
Enterprise Value€6.69B
Total Cash (Recent Filing)€1.27B
Total Debt (Recent Filing)€1.93B
Price to Earnings (P/E)36.0
Beta0.14
Next Earnings
Aug 26, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding195,000,000
10 Day Avg. Volume0
30 Day Avg. Volume91
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.47
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)€1.03B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilityThe balance sheet shows substantial equity and only moderate leverage (debt/equity ~0.36), providing financial flexibility to fund operations, absorb shocks, and support investment or working capital needs. This structural strength helps sustain the business through multi-quarter cyclical swings.
Positive Cash GenerationConsistent positive operating cash flow and meaningful free cash flow (FCF covers ~77% of net income) demonstrate the company converts earnings into cash. Durable cash generation supports dividends, capex and debt service, improving long-term operational resilience despite earnings volatility.
Diversified Pharma Product MixA business model spanning APIs, finished dosages and chemical intermediates diversifies revenue across upstream and downstream pharma supply chains. Structural diversification reduces dependence on a single product or channel, smoothing demand and protecting margins over multiple quarters.
Bears Say
Sharp Revenue DeclineA ~33% TTM revenue decline signals structural weakness in demand, pricing or customer mix. Loss of scale can persistently raise unit costs and squeeze margins, requiring material product portfolio or commercial recovery over several quarters to restore prior profitability levels.
Margin CompressionSignificant gross and net margin deterioration points to pricing pressure, mix shift, or higher input costs. Sustained margin erosion limits reinvestment, reduces free cash flow potential and weakens return on capital, making multi-quarter recovery harder without strategic product or cost fixes.
Rising Leverage And Weaker ReturnsLeverage has increased while ROE declined, raising financial risk. Higher debt with lower returns narrows the cushion for demand shocks and may constrain funding for R&D or capex. If profitability does not recover, leverage could pressure liquidity and strategic flexibility.
Shandong Xinhua Pharmaceutical Company Limited Class H News
XIN FAQ
What was Shandong Xinhua Pharmaceutical Company Limited Class H’s price range in the past 12 months?
Shandong Xinhua Pharmaceutical Company Limited Class H lowest stock price was €0.56 and its highest was €0.89 in the past 12 months.
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap?
Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap is €1.01B.
When is Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date?
Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date is Aug 26, 2026 which is in 22 days.
How were Shandong Xinhua Pharmaceutical Company Limited Class H’s earnings last quarter?
Shandong Xinhua Pharmaceutical Company Limited Class H released its earnings results on Apr 28, 2026. The company reported €0.015 earnings per share for the quarter, missing the consensus estimate of €0.023 by -€0.008.
Is Shandong Xinhua Pharmaceutical Company Limited Class H overvalued?
According to Wall Street analysts Shandong Xinhua Pharmaceutical Company Limited Class H’s price is currently Overvalued.
Does Shandong Xinhua Pharmaceutical Company Limited Class H pay dividends?
Shandong Xinhua Pharmaceutical Company Limited Class H does not currently pay dividends.
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate?
Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate is 0.02.
How many shares outstanding does Shandong Xinhua Pharmaceutical Company Limited Class H have?
Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding.
What happened to Shandong Xinhua Pharmaceutical Company Limited Class H’s price movement after its last earnings report?
Shandong Xinhua Pharmaceutical Company Limited Class H reported an EPS of €0.015 in its last earnings report, missing expectations of €0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shandong Xinhua Pharmaceutical Company Limited Class H?
Currently, no hedge funds are holding shares in DE:XIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shandong Xinhua Pharmaceutical Company Limited Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.94%
12-Months-Change
Fundamentals
Return on Equity
2.60%
Trailing 12-Months
Asset Growth
3.49%
Trailing 12-Months
Company Description
Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
Shandong Xinhua Pharmaceutical Company Limited Class H (XIN) Earnings & Revenues
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―